ZNTL stock forecast, quote, news & analysis
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC)... Show more
Why Zentalis Pharmaceuticals (ZNTL) Stock Is Up +11.6% in the Last 30 Days
Key Takeaways
- ZNTL gained approximately 11.6% over the last 30 days, climbing from $4.04 to $4.51, driven primarily by a major analyst initiation and clinical catalyst announcements.
- Mizuho Securities initiated coverage with an Outperform rating and an $8.00 price target on July 17, triggering a single-day surge of nearly 12%.
- The company announced its lead asset azenosertib will be featured in a rapid oral presentation at the ESMO Congress 2026, highlighting overall survival data from the DENALI Part 1b study.
- Over the last quarter, ZNTL rose approximately 13.9%, reflecting sustained investor optimism around the azenosertib clinical pipeline and regulatory milestones.
- The DENALI Phase 2 topline readout, expected by year-end 2026, remains the most significant near-term catalyst for the stock.
Zentalis Pharmaceuticals (ZNTL) Company Overview and Market Position
Zentalis Pharmaceuticals is a clinical-stage oncology company focused on developing small molecule therapeutics for difficult-to-treat cancers. Its lead candidate, azenosertib (ZN-c3), is a potentially first-in-class, orally bioavailable WEE1 inhibitor designed as a biomarker-driven, non-chemotherapy treatment approach. The company's primary focus is Cyclin E1-positive platinum-resistant ovarian cancer (PROC), an indication with high unmet need that accounts for approximately 50% of PROC patients and currently has no approved targeted therapy. Azenosertib has received Fast Track Designation from the FDA. Zentalis is advancing the candidate through the registration-intended DENALI Phase 2 trial and the confirmatory ASPENOVA Phase 3 trial simultaneously. With a market capitalization of approximately $321 million as of late July 2026 and $211.8 million in cash as of March 31, 2026, the company has a projected runway into late 2027.
Zentalis Pharmaceuticals (ZNTL) Stock Price Performance: Last 30 Days vs. Quarter
ZNTL shares appreciated approximately 11.6% over the trailing 30-day period, rising from a closing price of $4.04 on June 26 to $4.51 on July 27. The move was not linear; after trading in a relatively tight range through early July, the stock experienced a pronounced breakout on July 17, surging from $4.57 to $5.11 in a single session on volume exceeding 2.2 million shares — more than double the daily average. Over the full quarter, the stock gained approximately 13.9%, extending a powerful year-to-date rally of more than 230%. The quarterly trend reflects a steady climb from the sub-$4.00 range in late April to the mid-$4.00-to-low-$5.00 range by late July, punctuated by volatility around clinical and analyst-driven events.
What Drove ZNTL Stock Price in the Last 30 Days
The most impactful catalyst during the 30-day window was Mizuho Securities' initiation of coverage on July 17 with an Outperform rating and an $8.00 price target, representing roughly 75% upside from prevailing levels. Analyst Graig Suvannavejh cited attractive risk-reward ahead of the DENALI Part 2 topline readout, assigning a 60% probability of success for azenosertib and projecting approximately $1.5 billion in peak worldwide risk-unadjusted sales in platinum-resistant ovarian cancer. The same day, Zentalis announced that overall survival data from the DENALI Part 1b study was accepted as a rapid oral presentation at the ESMO Congress 2026, scheduled for October 23–27 in Madrid. This dual catalyst day drove a nearly 12% single-session gain. Broader sentiment was supported by ongoing enrollment progress across DENALI Parts 2b and 2c and the ASPENOVA Phase 3 confirmatory trial, as well as institutional accumulation noted in recent quarters from firms including Millennium Management and 5AM Venture Management.
What Drove ZNTL Stock Performance Over the Last Quarter
The quarterly advance reflects a series of clinical execution milestones that reinforced confidence in azenosertib's regulatory pathway. In April, Zentalis selected the 400 mg once-daily 5:2 dosing regimen as the pivotal monotherapy dose for the DENALI registration-intended program based on a pre-specified interim analysis showing a favorable benefit-risk profile. In May, the company dosed the first patient in the ASPENOVA Phase 3 confirmatory trial and reported first-quarter financial results showing $211.8 million in cash — sufficient runway into late 2027. Presentations at AACR 2026 highlighted preclinical activity of azenosertib combinations in ADC-resistant triple-negative breast cancer, supporting pipeline expansion. Additionally, an abstract for the ASCO 2026 Annual Meeting was accepted featuring azenosertib plus paclitaxel combination data from the MUIR trial. Collectively, these developments shifted the narrative from early-stage to late-stage execution, attracting fresh institutional and analyst attention throughout the quarter.
Trending AI Robots
For traders seeking data-driven insights beyond traditional research, Tickeron's Trending AI Robots page showcases a curated selection of top-performing AI-powered trading bots. While Tickeron offers hundreds of AI trading bots covering thousands of tickers across diverse strategies and timeframes, only the most relevant and highest-performing bots appear in this dynamically updated section. Each bot is designed with a distinct methodology — ranging from swing trading and trend-following to pattern recognition and technical analysis — enabling users to explore automated strategies aligned with their individual trading objectives and risk tolerance. Browsing the Trending AI Robots page can help traders identify AI-driven approaches that complement their own market analysis.
ZNTL Stock Forecast Drivers: What Investors Should Watch Next
The single most consequential event on Zentalis' horizon is the DENALI Part 2 topline readout expected by year-end 2026, which could support an accelerated approval filing with the FDA if positive. Ahead of that binary catalyst, the ESMO Congress 2026 rapid oral presentation in late October will provide the first detailed look at overall survival data from DENALI Part 1b, potentially shaping expectations for the Part 2 readout. Investors should also monitor enrollment completion announcements for DENALI Parts 2b and 2c, updates on the ASPENOVA Phase 3 trial, and any regulatory interactions with the FDA regarding the accelerated approval pathway. Macroeconomic factors including interest rate policy and biotech sector fund flows may influence sentiment, and the company's cash burn rate relative to its late-2027 runway will remain an area of scrutiny. The upcoming Q2 2026 earnings report, expected in early August, will provide updated financials and pipeline commentary from management.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ZNTL sees its Stochastic Oscillator recovers from oversold territory
On July 29, 2026, the Stochastic Oscillator for ZNTL moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 66 instances where the indicator left the oversold zone. In of the 66 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
ZNTL moved above its 50-day moving average on June 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ZNTL crossed bullishly above the 50-day moving average on July 01, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZNTL advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 125 cases where ZNTL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ZNTL moved out of overbought territory on July 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZNTL as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ZNTL turned negative on July 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZNTL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ZNTL broke above its upper Bollinger Band on July 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.847) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (6.812) is also within normal values, averaging (420.906).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZNTL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZNTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company, which focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer
Industry Biotechnology